Study on the effect of Archartan on reducing blood pressure and improving metabolic indexes in hypertensive patients with metabolic syndrome

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300071499

Enrollment

Unknown

Registered

2023-05-16

Start date

2023-06-01

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Azisartan group:Azisartan medication taken orally

irbesartan group:Oral irbesartan medication

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Mild to moderate essential hypertension patients with metabolic syndrome were diagnosed. The diagnostic criteria for mild to moderate hypertension were set as SBP>=140 mmHg and =90 mmHg and = 90 cm in men and >= 85 cm in women; (2) Hyperglycemia: fasting blood sugar >= 6.10 mmol/L (110 mg/dl) or blood sugar >= 7.80 mmol/L (140 mg/dl) 2 h after glucose loading and/or diagnosed diabetes mellitus and treatment; (3) Hypertension: blood pressure >= 130/85 mmHg and/or have been diagnosed with hypertension and treated; (4) Fasting TG >= 1.7 mmol/L (150 mg/dl); (5) Fasting HDL-C < 1.0 mmol/L (40 mg/dl). (2) Aged 18-75. (3) Accept the medication and follow-up required by the project process, and sign the informed consent

Exclusion criteria

Exclusion criteria: (1) Patients with secondary hypertension (2) Participants in other clinical drugs in the past 3 months (3) Patients with history of cerebrovascular accidents, severe trauma, and major surgery in the past 6 months (4) pregnant and lactating women (5) patients with serious adverse reactions or intolerance to ARB drugs in the past (6) patients with serious chronic diseases, Severe liver and kidney insufficiency; Infectious diseases, autoimmune diseases, tumors; Or are taking drugs that may interfere with the results of the study or hypoglycemic or lipid-regulating drugs. Who are considered unfit by the researcher to participate in the project

Design outcomes

Primary

Measure	Time frame
blood pressure;blood sugar;blood triglyceride;blood Total cholesterol;blood Low density lipoprotein cholesterol;	—

Secondary

Measure	Time frame
Uric acid;Waist circumference;C-reactive protein;C-reactive protein;creatinine;	—

Countries

China

Contacts

Public ContactQiuping Zhao

Fuwai Central China Cardiovascular Hospital

qiupingzhao6699@163.com+86 136 1382 4917

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026